Skip to main navigation Skip to search Skip to main content

Understanding patient perspectives in the management of their muscle-invasive bladder cancer

  • Deepro Chowdhury
  • , Andrea B. Apolo
  • , Di Maria Jiang
  • , Eila C. Skinner
  • , Stephanie Chisolm
  • , Rick Bangs
  • , Manjula Maganti
  • , Gary D. Steinberg
  • , Matthew Kaag
  • , Jason A. Efstathiou
  • , Srikala S. Sridhar

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To evaluate the impact of advocacy efforts by organisations such as the Bladder Cancer Advocacy Network (BCAN) to increase awareness about the signs, symptoms, diagnosis, treatment and need for a multidisciplinary approach to the care of patients with muscle-invasive bladder cancer (MIBC). Materials and Methods: We developed a 32-question survey with input from physicians, nurses, patients and caregivers. The survey was posted on the BCAN website between August 2013 and September 2014 (Cohort A) and again between June 2023 and April 2024 (Cohort B). Questions focused on time from initial symptoms to diagnosis and treatment, proportion seeing a medical oncologist or radiation oncologist, treatments offered/received, and patient satisfaction with their treatment choices. Results: Overall, 337 self-selected patients mostly white males from the US or Canada, with at least an undergraduate education completed the survey. There were 243 patients in Cohort A and 94 patients in Cohort B. The median age (range) at diagnosis was 61 (31–93) in Cohort A and 63 (38–87) in Cohort B. The most common presenting symptom was hematuria. In Cohorts A and B, 35% vs 30% (P = 0.56) waited >3 months to seek medical attention, and in 38% vs 43% (P = 0.76) it took >3 months to obtain a diagnosis. Men were more likely than women to be diagnosed within 1–2 months in both cohorts (Cohort A: 68% vs 47%; P = 0.03, Cohort B: 70% vs 37%; P = 0.03). Preoperative consultation with a radiation oncologist and bladder-sparing use were infrequent. More patients in Cohort A (77%) felt they had enough time to make decisions compared to Cohort B (67%) (P = 0.004). Most patients were satisfied with their treatment choices. Conclusions: There are ongoing areas of unmet need in MIBC, including reducing time to definitive diagnosis and treatment, especially in women, and increasing multidisciplinary assessments prior to definitive surgery. Respondents were self-selected, had access to the BCAN website, and were highly educated, potentially limiting the generalizability of these results.

Original languageEnglish (US)
Pages (from-to)493-499
Number of pages7
JournalBJU International
Volume136
Issue number3
DOIs
StatePublished - Sep 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint

Dive into the research topics of 'Understanding patient perspectives in the management of their muscle-invasive bladder cancer'. Together they form a unique fingerprint.

Cite this